Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues: |
| Diagnostics | 162.1 | 155.9 | 151.0 | 139.8 | 130.6 | 127.8 | 123.3 | 113.7 |
| Life Science | 139.5 | 177.1 | 192.5 | 199.5 | 182.7 | 190.1 | 182.6 | 213.5 |
| Total revenues | 301.6 | 333.0 | 343.5 | 339.3 | 313.3 | 317.9 | 305.8 | 327.1 |
| Revenue growth [+] | -3.7% | 4.8% | 12.3% | 3.7% | 4.7% | 25.3% | 27.2% | 60.4% |
| Diagnostics | 24.1% | 22.0% | 22.5% | 23.0% | 12.0% | 5.5% | -1.2% | -16.6% |
| Life Science | -23.6% | -6.8% | 5.4% | -6.5% | 0.1% | 43.5% | 57.9% | 215.1% |
| Cost of goods sold | 130.9 | 144.7 | 144.5 | 139.8 | 124.6 | 116.7 | 111.3 | 113.8 |
| Gross profit | 170.7 | 188.4 | 199.1 | 199.5 | 188.8 | 201.1 | 194.5 | 213.4 |
| Gross margin | 56.6% | 56.6% | 57.9% | 58.8% | 60.2% | 63.3% | 63.6% | 65.2% |
| Selling, general and administrative [+] | 85.4 | 88.4 | 89.5 | 86.4 | 79.8 | 76.3 | 75.7 | 76.4 |
| Sales and marketing | 31.8 | 31.3 | 30.4 | 28.5 | 27.5 | 26.8 | 26.7 | 26.8 |
| General and administrative | 53.6 | 57.1 | 59.1 | 57.9 | 52.3 | 49.5 | 48.9 | 49.6 |
| Research and development | 24.3 | 24.3 | 24.0 | 24.1 | 24.5 | 23.9 | 24.8 | 25.4 |
| Other operating expenses | 52.2 | 19.6 | 18.2 | | 6.8 | 6.5 | 6.4 | |
| EBITDA [+] | 25.3 | 72.5 | 83.9 | 98.4 | 93.5 | 109.7 | 103.0 | 120.8 |
| EBITDA growth | -72.9% | -33.9% | -18.6% | -18.5% | -6.4% | 61.0% | 50.2% | 161.5% |
| EBITDA margin | 8.4% | 21.8% | 24.4% | 29.0% | 29.8% | 34.5% | 33.7% | 36.9% |
| Depreciation | 6.5 | 6.6 | 6.8 | 6.8 | 6.7 | 6.5 | 6.8 | 6.5 |
| EBITA | 18.8 | 65.9 | 77.1 | 91.6 | 86.8 | 103.2 | 96.2 | 114.3 |
| EBITA margin | 6.2% | 19.8% | 22.4% | 27.0% | 27.7% | 32.5% | 31.5% | 34.9% |
| Amortization of intangibles | 10.0 | 9.9 | 9.8 | 9.4 | 9.0 | 8.8 | 8.6 | 8.7 |
| EBIT [+] | 8.8 | 56.0 | 67.3 | 82.2 | 77.7 | 94.4 | 87.7 | 105.6 |
| EBIT growth | -88.7% | -40.7% | -23.2% | -22.2% | -9.1% | 73.1% | 56.4% | 205.9% |
| EBIT margin | 2.9% | 16.8% | 19.6% | 24.2% | 24.8% | 29.7% | 28.7% | 32.3% |
| Non-recurring items [+] | 2.8 | 1.6 | 9.1 | 1.6 | | 1.3 | -6.4 | -7.4 |
| Restructuring charges | 2.3 | 1.1 | 4.3 | 0.4 | | | -3.1 | |
| Legal settlement | | | | 0.5 | | | | 2.4 |
| Loss on contingent liability | | | | | | -0.9 | -4.4 | -6.9 |
| Interest expense, net [+] | 0.9 | 1.2 | 1.4 | 1.6 | 1.7 | 1.8 | 2.1 | 2.3 |
| Interest expense | 1.0 | 1.2 | 1.4 | 1.6 | 1.7 | 1.9 | 2.1 | 2.3 |
| Interest income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | 0.0 |
| Other income (expense), net [+] | 0.4 | 1.1 | 0.7 | 0.4 | -1.0 | -0.7 | -1.6 | -0.8 |
| Other | 7.9 | 7.9 | 7.7 | 6.7 | 5.3 | 4.6 | 3.6 | 3.1 |
| Pre-tax income | 5.5 | 54.3 | 57.5 | 79.4 | 76.0 | 90.5 | 90.3 | 109.9 |
| Income taxes | 8.2 | 11.9 | 14.1 | 17.0 | 16.0 | 19.0 | 19.1 | 22.8 |
| Tax rate | | | | 21.4% | 21.0% | 21.1% | 21.1% | 20.8% |
| Net income | -2.7 | 42.5 | 43.4 | 62.4 | 60.0 | 71.4 | 71.2 | 87.1 |
| Net margin | -0.9% | 12.7% | 12.6% | 18.4% | 19.1% | 22.5% | 23.3% | 26.6% |
| |
| Basic EPS [+] | ($0.06) | $0.98 | $1.00 | $1.44 | $1.38 | $1.65 | $1.65 | $2.02 |
| Growth | -104.5% | -41.0% | -39.5% | -29.0% | -15.3% | 53.2% | 61.3% | 304.7% |
| Diluted EPS [+] | ($0.06) | $0.96 | $0.98 | $1.42 | $1.36 | $1.62 | $1.63 | $2.00 |
| Growth | -104.5% | -40.9% | -39.6% | -29.2% | -16.0% | 51.4% | 59.8% | 301.4% |
| |
| |
| Shares outstanding (basic) [+] | 43.7 | 43.5 | 43.5 | 43.4 | 43.3 | 43.2 | 43.1 | 43.0 |
| Growth | 0.8% | 0.7% | 0.8% | 0.9% | 1.0% | 0.9% | 0.9% | 0.7% |
| Shares outstanding (diluted) [+] | 44.3 | 44.3 | 44.2 | 44.1 | 44.1 | 44.0 | 43.8 | 43.6 |
| Growth | 0.4% | 0.6% | 0.9% | 1.2% | 1.8% | 2.1% | 1.8% | 1.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|